A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04322604 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

181

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions

DRUG: lirentelimab (AK002)
OTHER: Placebo

Sponsor

Allakos Inc.